| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| BFRIBiofrontera Inc. | 9.73M | 0.84 | -0.26 | 9.49% | -47.28% | -384.98% | 1.11 | |
| EOLSEvolus, Inc. | 324.1M | 5.00 | -6.17 | 31.76% | -20.49% | -9.13% | 23.54 | |
| DERMJourney Medical Corporation | 176.7M | 8.36 | -11.61 | -29.11% | -15.49% | -45.4% | 1.28 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 26.18M | 18.85M | 24.1M | 28.67M | 34.07M | 37.3M |
| Revenue Growth % | - | -0.28% | 0.28% | 0.19% | 0.19% | 0.09% |
| Cost of Goods Sold | 12.41M | 9.07M | 12.74M | 15.19M | 17.44M | 18.61M |
| COGS % of Revenue | 0.47% | 0.48% | 0.53% | 0.53% | 0.51% | 0.5% |
| Gross Profit | 13.77M | 9.78M | 11.36M | 13.49M | 16.63M | 18.7M |
| Gross Margin % | 0.53% | 0.52% | 0.47% | 0.47% | 0.49% | 0.5% |
| Gross Profit Growth % | - | -0.29% | 0.16% | 0.19% | 0.23% | 0.12% |
| Operating Expenses | 28.7M | 19.39M | 36.56M | 32.07M | 39.3M | 35.92M |
| OpEx % of Revenue | 1.1% | 1.03% | 1.52% | 1.12% | 1.15% | 0.96% |
| Selling, General & Admin | 28.7M | 18.12M | 37.21M | 35.87M | 39.13M | 33.84M |
| SG&A % of Revenue | 1.1% | 0.96% | 1.54% | 1.25% | 1.15% | 0.91% |
| Research & Development | 0 | 0 | 0 | 0 | 77K | 2.09M |
| R&D % of Revenue | - | - | - | - | 0% | 0.06% |
| Other Operating Expenses | 0 | 1.27M | -650K | -3.8M | 100K | 0 |
| Operating Income | -14.92M | -9.61M | -25.2M | -18.58M | -22.68M | -17.21M |
| Operating Margin % | -0.57% | -0.51% | -1.05% | -0.65% | -0.67% | -0.46% |
| Operating Income Growth % | - | 0.36% | -1.62% | 0.26% | -0.22% | 0.24% |
| EBITDA | -14.26M | -9.04M | -24.66M | -17.41M | -21.61M | -16.06M |
| EBITDA Margin % | -0.54% | -0.48% | -1.02% | -0.61% | -0.63% | -0.43% |
| EBITDA Growth % | - | 0.37% | -1.73% | 0.29% | -0.24% | 0.26% |
| D&A (Non-Cash Add-back) | 667K | 562K | 540K | 1.17M | 1.06M | 1.15M |
| EBIT | -8.79M | -8.03M | -37.3M | -238K | -19.52M | -15.63M |
| Net Interest Income | -2.13M | -2.87M | -344K | -195K | -468K | -2.08M |
| Interest Income | 25K | 28K | 16K | 175K | 132K | 30K |
| Interest Expense | 2.16M | 2.9M | 360K | 370K | 600K | 2.11M |
| Other Income/Expense | 3.97M | -1.32M | -12.46M | 17.97M | 2.56M | -527K |
| Pretax Income | -10.95M | -10.92M | -37.66M | -608K | -20.12M | -17.74M |
| Pretax Margin % | -0.42% | -0.58% | -1.56% | -0.02% | -0.59% | -0.48% |
| Income Tax | 33K | 64K | 56K | 32K | 14K | 22K |
| Effective Tax Rate % | 1% | 1.01% | 1% | 1.05% | 1% | 1% |
| Net Income | -10.98M | -10.99M | -37.71M | -640K | -20.13M | -17.76M |
| Net Margin % | -0.42% | -0.58% | -1.56% | -0.02% | -0.59% | -0.48% |
| Net Income Growth % | - | -0% | -2.43% | 0.98% | -30.45% | 0.12% |
| Net Income (Continuing) | -10.98M | -10.99M | -37.71M | -640K | -20.13M | -17.76M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -18.09 | -18.94 | -44.10 | -0.61 | -13.02 | -3.22 |
| EPS Growth % | - | -0.05% | -1.33% | 0.99% | -20.34% | 0.75% |
| EPS (Basic) | -18.09 | -18.94 | -44.10 | -0.61 | -13.02 | -3.22 |
| Diluted Shares Outstanding | 607K | 580K | 855.24K | 1.06M | 1.55M | 5.52M |
| Basic Shares Outstanding | 607K | 580K | 855.24K | 1.06M | 1.55M | 5.52M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 23.47M | 19.58M | 46.42M | 43.14M | 23.07M | 20.7M |
| Cash & Short-Term Investments | 7.3M | 8.08M | 24.55M | 27.76M | 1.42M | 5.91M |
| Cash Only | 7.3M | 8.08M | 24.55M | 17.21M | 1.34M | 5.91M |
| Short-Term Investments | 0 | 0 | 0 | 10.55M | 78K | 7K |
| Accounts Receivable | 4.79M | 3.29M | 3.78M | 7.41M | 5.16M | 5.32M |
| Days Sales Outstanding | 66.72 | 63.69 | 57.31 | 94.27 | 55.3 | 52.01 |
| Inventory | 10.48M | 7.09M | 4.46M | 7.17M | 10.91M | 6.65M |
| Days Inventory Outstanding | 308.29 | 285.49 | 127.7 | 172.3 | 228.24 | 130.37 |
| Other Current Assets | 186K | 619K | 12.81M | 286K | 5.28M | 2.83M |
| Total Non-Current Assets | 5.28M | 4.56M | 6.8M | 7.74M | 4.86M | 1.4M |
| Property, Plant & Equipment | 503K | 370K | 267K | 1.58M | 1.75M | 983K |
| Fixed Asset Turnover | 52.05x | 50.94x | 90.26x | 18.16x | 19.51x | 37.95x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4.29M | 3.87M | 3.45M | 3.03M | 2.63M | 35K |
| Long-Term Investments | 0 | 0 | 2.81M | 0 | 0 | 0 |
| Other Non-Current Assets | 494K | 323K | 3.08M | 3.13M | 482K | 383K |
| Total Assets | 28.75M | 24.14M | 53.22M | 50.88M | 27.93M | 22.1M |
| Asset Turnover | 0.91x | 0.78x | 0.45x | 0.56x | 1.22x | 1.69x |
| Asset Growth % | - | -0.16% | 1.2% | -0.04% | -0.45% | -0.21% |
| Total Current Liabilities | 11.74M | 4.42M | 13.84M | 20.89M | 18.09M | 12.02M |
| Accounts Payable | 7.81M | 1.51M | 658K | 1.28M | 8.91M | 1.86M |
| Days Payables Outstanding | 229.86 | 60.95 | 18.85 | 30.72 | 186.35 | 36.41 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 3.9M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 1000K | 0 | 0 |
| Other Current Liabilities | 1.88M | 569K | 6.7M | 3.3M | 3.02M | 1.05M |
| Current Ratio | 2.00x | 4.43x | 3.36x | 2.06x | 1.28x | 1.72x |
| Quick Ratio | 1.11x | 2.82x | 3.03x | 1.72x | 0.67x | 1.17x |
| Cash Conversion Cycle | 145.15 | 288.22 | 166.16 | 235.85 | 97.19 | 145.97 |
| Total Non-Current Liabilities | 47.19M | 13.89M | 28.05M | 6.11M | 5.05M | 5.65M |
| Long-Term Debt | 38.2M | 0 | 0 | 0 | 0 | 4.1M |
| Capital Lease Obligations | 0 | 0 | 0 | 848K | 804K | 276K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 58K | 62K | 18.5M | 2.86M | 4.25M | 1.27M |
| Total Liabilities | 58.93M | 18.31M | 41.88M | 27.01M | 23.14M | 17.67M |
| Total Debt | 38.2M | 0 | 0 | 1.35M | 5.4M | 4.92M |
| Net Debt | 30.9M | -8.08M | -24.55M | -15.86M | 4.06M | -983K |
| Debt / Equity | - | - | - | 0.06x | 1.13x | 1.11x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -6.91x | -3.32x | -70.00x | -50.22x | -37.80x | -8.17x |
| Total Equity | -30.18M | 5.83M | 11.34M | 23.88M | 4.79M | 4.43M |
| Equity Growth % | - | 1.19% | 0.95% | 1.11% | -0.8% | -0.08% |
| Book Value per Share | -49.72 | 10.05 | 13.26 | 22.59 | 3.10 | 0.80 |
| Total Shareholders' Equity | -30.18M | 5.83M | 11.34M | 23.88M | 4.79M | 4.43M |
| Common Stock | 0 | 8K | 17K | 1K | 2K | 9K |
| Retained Earnings | -30.18M | -41.17M | -78.88M | -79.52M | -99.65M | -117.41M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -37.68M | -12.37M | -26.71M | -16.2M | -24.89M | -10.27M |
| Operating CF Margin % | -1.44% | -0.66% | -1.11% | -0.56% | -0.73% | -0.28% |
| Operating CF Growth % | - | 0.67% | -1.16% | 0.39% | -0.54% | 0.59% |
| Net Income | -10.98M | -10.99M | -37.71M | -640K | -20.13M | -17.76M |
| Depreciation & Amortization | 667K | 562K | 540K | 1.17M | 1.06M | 1.15M |
| Stock-Based Compensation | 0 | 0 | 129K | 1.85M | 1.04M | 1.02M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -3.42M | 883K | 11.83M | -21.37M | -2.48M | -891K |
| Working Capital Changes | -23.94M | -2.83M | -1.5M | 2.79M | -4.39M | 6.21M |
| Change in Receivables | -757K | 1.17M | -12M | 4.92M | 4.93M | -313K |
| Change in Inventory | -3.54M | -273K | 2.59M | -2.81M | -3.75M | 4.23M |
| Change in Payables | 1.44M | -3.4M | -773K | 0 | 6.42M | -1.81M |
| Cash from Investing | 25.39M | 0 | -11K | -5.16M | 619K | -3K |
| Capital Expenditures | -538K | 0 | -11K | -38K | -5K | -10K |
| CapEx % of Revenue | 0.02% | - | 0% | 0% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -50K |
| Cash from Financing | 16.4M | 13.19M | 43.19M | 14.02M | 8.41M | 14.84M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 2.9M | 4.4M | 13.25M | 4.63M | 0 | 7.44M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -38.22M | -12.37M | -26.73M | -16.24M | -24.9M | -10.33M |
| FCF Margin % | -1.46% | -0.66% | -1.11% | -0.57% | -0.73% | -0.28% |
| FCF Growth % | - | 0.68% | -1.16% | 0.39% | -0.53% | 0.59% |
| FCF per Share | -62.96 | -21.33 | -31.25 | -15.36 | -16.10 | -1.87 |
| FCF Conversion (FCF/Net Income) | 3.43x | 1.13x | 0.71x | 25.31x | 1.24x | 0.58x |
| Interest Paid | 1.71M | 3.07M | 2K | 1K | 147K | 1.73M |
| Taxes Paid | 50K | 64K | 56K | 32K | 15K | 24K |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -188.52% | -439.39% | -3.63% | -140.43% | -384.98% |
| Return on Invested Capital (ROIC) | -1556.54% | - | - | -173.85% | -201.69% | -209.9% |
| Gross Margin | 52.61% | 51.9% | 47.13% | 47.04% | 48.8% | 50.12% |
| Net Margin | -41.95% | -58.29% | -156.49% | -2.23% | -59.09% | -47.61% |
| Debt / Equity | - | - | - | 0.06x | 1.13x | 1.11x |
| Interest Coverage | -6.91x | -3.32x | -70.00x | -50.22x | -37.80x | -8.17x |
| FCF Conversion | 3.43x | 1.13x | 0.71x | 25.31x | 1.24x | 0.58x |
| Revenue Growth | - | -28.01% | 27.86% | 18.98% | 18.82% | 9.49% |
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Government and Payor Rebates | - | 264K | 310K |
| Government and Payor Rebates Growth | - | - | 17.42% |
| Co-pay Assistance Program | - | 675K | 165K |
| Co-pay Assistance Program Growth | - | - | -75.56% |
| Returns | - | 53K | 52K |
| Returns Growth | - | - | -1.89% |
| Prompt Pay Discounts | - | 67K | 6K |
| Prompt Pay Discounts Growth | - | - | -91.04% |
| Revenues Related Party | 57K | - | - |
| Revenues Related Party Growth | - | - | - |
Biofrontera Inc. (BFRI) reported $37.2M in revenue for fiscal year 2024. This represents a 42% increase from $26.2M in 2019.
Biofrontera Inc. (BFRI) grew revenue by 9.5% over the past year. This is steady growth.
Biofrontera Inc. (BFRI) reported a net loss of $17.6M for fiscal year 2024.
Biofrontera Inc. (BFRI) has a return on equity (ROE) of -385.0%. Negative ROE indicates the company is unprofitable.
Biofrontera Inc. (BFRI) had negative free cash flow of $12.0M in fiscal year 2024, likely due to heavy capital investments.